← Back to overview

REGN Regeneron Pharmaceuticals, Inc.

Biotechnology · $656.01 +0.63%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
45.9
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
653.27 / 760.36 / 442.19
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
-26.16 / -26.16
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
16.0
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
68.78B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
0.57%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
541.00 – 821.11
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Regeneron Pharmaceuticals, Inc. is trading at $656.01, +0.63% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
The 50-day average is above the 200-day average ("golden cross" territory) — a commonly watched bullish signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

The Scientist With 1,000 Patents Fueling a Drug Powerhouse
The Wall Street Journal · 2026-07-24 17:40
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks · 2026-07-23 14:00
Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
Barchart · 2026-07-23 11:47
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785
MT Newswires · 2026-07-21 16:22
Guggenheim Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $995, Maintains Buy Rating
MT Newswires · 2026-07-21 10:59
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
GlobeNewswire · 2026-07-20 23:31
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating
MT Newswires · 2026-07-20 12:37
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
PR Newswire · 2026-07-20 11:30
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.